Literature DB >> 6145516

Sulfasalazine-induced colitis complicating idiopathic ulcerative colitis.

F A Ring, N B Hershfield, G A Machin, R B Scott.   

Abstract

A diagnosis of idiopathic ulcerative colitis was made in a previously healthy 9-year-old boy. Symptoms persisted despite therapy with sulfasalazine, 50 mg/kg daily, but they eventually responded to treatment with parenteral nutrition and prednisone, 40 mg daily. Metronidazole was also given to eradicate persistent Dientamoeba fragilis from the stools. The symptoms resolved over 3 weeks, and the daily dose of prednisone was tapered. On two subsequent occasions a challenge with sulfasalazine caused an immediate recurrence of loose, blood-streaked stools and of nonspecific histologic features of ulcerative colitis, which resolved when the sulfasalazine was discontinued.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145516      PMCID: PMC1483351     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  8 in total

1.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.

Authors:  J E LENNARD-JONES; J J MISIEWICZ; A M CONNELL; J H BARON; F A JONES
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

Review 2.  Drug therapy: Sulfasalazine.

Authors:  P Goldman; M A Peppercorn
Journal:  N Engl J Med       Date:  1975-07-03       Impact factor: 91.245

3.  Bloody diarrhea--a new complication of sulfasalazine.

Authors:  S L Werlin; R J Grand
Journal:  J Pediatr       Date:  1978-03       Impact factor: 4.406

4.  Sulfasalazine-induced exacerbation of ulcerative colitis.

Authors:  A G Schwartz; S R Targan; A Saxon; W M Weinstein
Journal:  N Engl J Med       Date:  1982-02-18       Impact factor: 91.245

5.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

6.  Dientamoeba fragilis. An intestinal pathogen in children?

Authors:  M J Spencer; L S Garcia; M R Chapin
Journal:  Am J Dis Child       Date:  1979-04

7.  Dientamoeba fragilis: a review with notes on its epidemiology, pathogenicity, mode of transmission, and diagnosis.

Authors:  J Yang; T Scholten
Journal:  Am J Trop Med Hyg       Date:  1977-01       Impact factor: 2.345

8.  Dientamoeba fragilis: a gastrointestinal protozoan infection in adults.

Authors:  M J Spencer; M R Chapin; L S Garcia
Journal:  Am J Gastroenterol       Date:  1982-08       Impact factor: 10.864

  8 in total
  6 in total

Review 1.  Dientamoeba fragilis, the Neglected Trichomonad of the Human Bowel.

Authors:  Damien Stark; Joel Barratt; Douglas Chan; John T Ellis
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 2.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

3.  Influence of olsalazine on gastrointestinal transit in ulcerative colitis.

Authors:  S S Rao; N W Read; C D Holdsworth
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

Review 4.  Comparative tolerability of therapies for ulcerative colitis.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy.

Authors:  H Sandberg-Gertzén; G Järnerot; K Bukhave; K Lauritsen; J Rask-Madsen
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

Review 6.  Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.

Authors:  G Järnerot
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.